
Imlunestrant Plus Abemaciclib Provides Consistent Benefit Across Key Subgroups of ER+ Advanced Breast Cancer
Imlunestrant (LY3484356) combined with abemaciclib (Verzenio) showcased consistent benefit over imlunestrant alone in CDK4/6 inhibitor–pretreated patients with estrogen receptor (ER)–positive, HER2-negative advanced breast cancer across clinically and …